Landec Corporation elects Ray Diradoorian to Board as Class 2 director

LIFECORE BIOMEDICAL, INC. DE

Board expanded to 11 members; Ray Diradoorian elected effective Jan 20, 2022.
Diradoorian appointed to Lifecore Focus Committee.
No material interest in transactions over $120k with the company.
Standard director compensation: $50k annual cash retainer plus $90k RSU award (initial $30k pro-rated).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ray Diradoorian

Director

LFCR · LIFECORE BIOMEDICAL, INC. DE

Effective: 2022-01-20
Filed: January 24, 2022, 6:59 PM ET

On January 20, 2022 the Board of Directors (the “Board”) of Landec Corporation (the “Company”) increased the size of the Board to 11 members and elected Ray Diradoorian to serve as a member of the Board, Class 2 Director and member of the Lifecore Focus Committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ray Diradoorian was elected as Director at LIFECORE BIOMEDICAL, INC. DE.

Action: elected
Role: Director

Exact text from the filing

On January 20, 2022 the Board of Directors (the “Board”) of Landec Corporation (the “Company”) increased the size of the Board to 11 members and elected Ray Diradoorian to serve as a member of the Board, Class 2 Director and member of the Lifecore Focus Committee.

View on SEC.gov

LIFECORE BIOMEDICAL, INC. DE filing history →

Source: SEC EDGAR

accession 0001005286-22-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.